FAIR LAWN, N.J.--(BUSINESS WIRE)--Vyteris, Inc. (OTC BB: VYTR), manufacturer of the first U.S. Food and Drug Administration (FDA)-approved active patch transdermal drug delivery system, announced an initiative to identify and target candidate drugs in the pain management field that could potentially be delivered using Vyteris’ active patch transdermal system.
